


Evolving strategies: Managing treatment of early-stage and advanced lung cancers

Symposium presentations available on demand from **Tuesday 22 September 2020, 09:00 (CEST)**

Live Q&A to take place **Thursday 24 September 2020, 16:15–17:15 (CEST)**



Faculty and agenda



David Spigel (Chair)

Extensive-stage SCLC: Changing the paradigm with immuno-oncology combinations



Tom John

Early-stage *EGFR* NSCLC: Targeted treatment options following complete surgical resection



Johan Vansteenkiste

Unresectable stage III NSCLC: Clinical advances in the implementation of immuno-oncology therapy



David Planchard

Locally advanced or metastatic *EGFR* NSCLC: Targeted treatment options to improve outcomes in the first-line setting and beyond progression

AstraZeneca's commitment to sustainability



\$15.5 million

invested in environmental efficiency projects in 2019 (NRRGG fund)



CPD A Lists

One of three companies worldwide to achieve double A listing for Climate Change and Water Security for four consecutive years



62% of our power

is sourced or generated from renewable sources



100% of API

(Active Pharmaceutical Ingredient) discharges from AstraZeneca sites were assessed as safe



18% reduction

in our water use since 2015



25% of our vehicles

in Europe, North America or Japan are hybrid or electric



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website